Vivek Subbiah: With Further Optimization Biomni Could Be Strong Research Partner for Scientists
Vivek Subbiah/ LinkedIn

Vivek Subbiah: With Further Optimization Biomni Could Be Strong Research Partner for Scientists

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:

“An AI co-scientist to accelerate biomedical research.

The AI agent Biomni performs research tasks across diverse biomedical fields; with further training and optimization, it could be a powerful research partner for scientists.”

Title: An AI co-scientist to accelerate biomedical research

Authors: Karen O’Leary

Read the Article

Other articles featuring Vivek Subbiah on OncoDaily.